[go: up one dir, main page]

WO2008136374A1 - Composition pharmaceutique destinée à l'inhibition d'une neuropathie périphérique provoquée par l'administration d'un agent anticancéreux - Google Patents

Composition pharmaceutique destinée à l'inhibition d'une neuropathie périphérique provoquée par l'administration d'un agent anticancéreux Download PDF

Info

Publication number
WO2008136374A1
WO2008136374A1 PCT/JP2008/058011 JP2008058011W WO2008136374A1 WO 2008136374 A1 WO2008136374 A1 WO 2008136374A1 JP 2008058011 W JP2008058011 W JP 2008058011W WO 2008136374 A1 WO2008136374 A1 WO 2008136374A1
Authority
WO
WIPO (PCT)
Prior art keywords
administration
pharmaceutical composition
anticancer agent
peripheral neuropathy
neuropathy caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/058011
Other languages
English (en)
Japanese (ja)
Inventor
Takashi Kyoi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Priority to JP2008521731A priority Critical patent/JP4208036B1/ja
Publication of WO2008136374A1 publication Critical patent/WO2008136374A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention a pour objet de produire principalement une composition pharmaceutique destinée à inhiber une neuropathie périphérique provoquée par l'administration d'un agent anticancéreux. L'invention concerne une composition pharmaceutique destinée à inhiber une neuropathie périphérique provoquée par l'administration d'un agent anticancéreux, laquelle composition contient en tant que principe actif, un composé choisi dans le groupe constitué d'acide (±)-1,8-diéthyl-1,3,4,9-tétrahydropyrano[3,4-b]indole-1-acétique, d'acide (+)-1,8-diéthyl-1,3,4,9-tétrahydropyrano[3,4-b]indole-1-acétique et d'acide (-)-1,8-diéthyl-1,3,4,9-tétrahydropyrano-[3,4-b]-indole-1-acétique ou l'un de leurs sels acceptables sur le plan pharmaceutique.
PCT/JP2008/058011 2007-04-26 2008-04-25 Composition pharmaceutique destinée à l'inhibition d'une neuropathie périphérique provoquée par l'administration d'un agent anticancéreux Ceased WO2008136374A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008521731A JP4208036B1 (ja) 2007-04-26 2008-04-25 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-116616 2007-04-26
JP2007116616 2007-04-26
JP2007326744 2007-12-19
JP2007-326744 2007-12-19

Publications (1)

Publication Number Publication Date
WO2008136374A1 true WO2008136374A1 (fr) 2008-11-13

Family

ID=39943483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058011 Ceased WO2008136374A1 (fr) 2007-04-26 2008-04-25 Composition pharmaceutique destinée à l'inhibition d'une neuropathie périphérique provoquée par l'administration d'un agent anticancéreux

Country Status (2)

Country Link
JP (3) JP4208036B1 (fr)
WO (1) WO2008136374A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014172846A (ja) * 2013-03-07 2014-09-22 Kyushu Univ がん化学療法剤に起因する末梢神経障害予防剤及び／又は治療剤
CN110151760A (zh) * 2019-06-06 2019-08-23 上海海洋大学 双吲哚化合物fgfc1在制备抗非小细胞肺癌药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2857392B1 (fr) 2012-05-02 2018-06-13 Japanese Foundation For Cancer Research Petit composé ciblant le tacc3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544757A (en) * 1984-02-16 1985-10-01 American Home Products Corporation Process for the resolution of pyrano[3,4-b]indole-1-acetic acids
JPH0840903A (ja) * 1994-07-29 1996-02-13 Synthelabo Sa 抗癌剤により誘発される末梢神経障害を予防するための医薬組成物
WO2004043454A1 (fr) * 2002-11-13 2004-05-27 Sigma-Tau Industrie Farmaceutiche Riunite Spa Acetyle-l-carnitine pour la prevention et/ou le traitement de neuropathies peripheriques induites par des agents anticancereux

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544757A (en) * 1984-02-16 1985-10-01 American Home Products Corporation Process for the resolution of pyrano[3,4-b]indole-1-acetic acids
JPH0840903A (ja) * 1994-07-29 1996-02-13 Synthelabo Sa 抗癌剤により誘発される末梢神経障害を予防するための医薬組成物
WO2004043454A1 (fr) * 2002-11-13 2004-05-27 Sigma-Tau Industrie Farmaceutiche Riunite Spa Acetyle-l-carnitine pour la prevention et/ou le traitement de neuropathies peripheriques induites par des agents anticancereux

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAWAI S.: "Yakubutsu Ryoho ni Kansuru Saikin no Shinpo Sentakuteki COX-2 Sogaiyaku no Shintenkai", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 60, no. 12, 2002, pages 2370 - 2377 *
TAKAHASHI T.: "Koganzai Toyo ni yoru neuropathic pain ni Taisuru COX-2 Sogaiyaku no Rinsho Oyo", PHARMA MEDICA, vol. 24, no. 2, 2006, pages 79 - 83 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014172846A (ja) * 2013-03-07 2014-09-22 Kyushu Univ がん化学療法剤に起因する末梢神経障害予防剤及び／又は治療剤
CN110151760A (zh) * 2019-06-06 2019-08-23 上海海洋大学 双吲哚化合物fgfc1在制备抗非小细胞肺癌药物中的应用
CN110151760B (zh) * 2019-06-06 2022-02-11 上海海洋大学 双吲哚化合物fgfc1在制备抗非小细胞肺癌药物中的应用

Also Published As

Publication number Publication date
JPWO2008136374A1 (ja) 2010-07-29
JP2009167164A (ja) 2009-07-30
JP4281845B1 (ja) 2009-06-17
JP2009167163A (ja) 2009-07-30
JP4208036B1 (ja) 2009-01-14

Similar Documents

Publication Publication Date Title
WO2005112633A3 (fr) Composes et compositions pour administration d’agents actifs
MX2007007458A (es) Derivados de quinazolina para inhibir crecimiento de celulas cancerigenas y metodo para la preparacion de los mismos.
WO2007138472A3 (fr) Dérivés de la triazolopyridazine
WO2002070438A3 (fr) Compositions permettant l'administration de biophosphonates
WO2006067614A3 (fr) Derives heteroaromatiques utiles en tant qu'agents anticancereux
WO2008121348A3 (fr) Antagonistes de récepteurs opioïdes périphériques, et leurs utilisations
WO2010030704A3 (fr) Analogues d’aminoglycosides antibactériens
WO2008143240A1 (fr) Préparation orale renfermant un acide organique spécifique et procédé d'amélioration de la propriété d'élution et de la stabilité chimique de la préparation orale
WO2007022255A3 (fr) Preparations pharmaceutiques a liberation prolongee
WO2006082523A3 (fr) Compositions pharmaceutiques de metformine
WO2010132757A3 (fr) Analogues d'aminoglycoside antibactériens
WO2009156951A3 (fr) Composés de 5,6,7,8-tétrahydro-imidazo[1,5-a]pyrazine
WO2008144269A3 (fr) Methodes d'utilisation d'antagonistes de vasopressine avec des agents chimiotherapeutiques a base d'anthracycline visant a reduire la cardiotoxicite et/ou ameliorer la survie
ZA200603538B (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
WO2011009714A3 (fr) Dérivés de sel de benzoquinolizinium comme agents anti-cancéreux
WO2005117895A3 (fr) Compositions contenant de la meloxicame
WO2006042954A8 (fr) Dérivés de 2-amido-4-phenylthiazole, leur préparation et leur application en thérapeutique
WO2007092157A9 (fr) 7-[1h-imidazol-4-yl) methyl]-5,6,7,8-tetrahydroquinoline
WO2007083188A3 (fr) Procédé amélioré de préparation d'un dérivé de 5h-pyrrolo [3,4-b] pyrazine optiquement actif
WO2005004915A3 (fr) Compositions contenant meloxicam
TW200626158A (en) Naphthaline derivatives
WO2004098594A3 (fr) Forme posologique contenant du pantoprazole en tant qu'ingredient actif
WO2006050002A3 (fr) Compositions destinees a l'administration controlee de composes pharmaceutiquement actifs
WO2010044097A3 (fr) Nouvelle forme pharmaceutique de palipéridone et procédé de préparation de celle-ci
WO2007080324A3 (fr) Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008521731

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752085

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08752085

Country of ref document: EP

Kind code of ref document: A1